Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

A population pharmacokinetic (PK) analysis was conducted to characterize sources of interpatient variability on the PK of TAK‐931, a cell division cycle 7 kinase inhibitor, in adult patients with advanced solid tumors using data from 198 patients who received oral TAK‐931 over the range of 30 to 150...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaofei, Ouerdani, Aziz, Diderichsen, Paul Matthias, Gupta, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297904/
https://www.ncbi.nlm.nih.gov/pubmed/34564871
http://dx.doi.org/10.1002/jcph.1974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297904/
https://www.ncbi.nlm.nih.gov/pubmed/34564871
http://dx.doi.org/10.1002/jcph.1974

Ejemplares similares